GlassScriptPhysician profile
Mandi D Conway
NPI 1598761330
$2,365.29
in general payments reported to CMS, 2019-2025
21 companies · $713 in 2025
The $713 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $120 · 2021: $93.33 · 2022: $791 · 2023: $163 · 2024: $53.51 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $929.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $566.15 | 2019-2025 | |
| Notal Vision, INC. | $383.04 | 2022 | |
| Genentech USA, INC. | $274.54 | 2021-2023 | Vabysmo |
| Alcon Vision LLC | $180.55 | 2022-2025 | Clareon Panoptix Pro, Unity |
| Glaukos Corporation | $167.93 | 2020-2025 | Idosetr |
| Mallinckrodt Hospital Products INC. | $114.78 | 2021-2024 | Acthar |
| Regeneron Healthcare Solutions, INC. | $98.83 | 2021-2025 | Eylea Hd |
| Dompe US, INC. | $95.30 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $77.19 | 2019 | |
| Alimera Sciences, INC. | $70.73 | 2023 | Iluvien |
| Astellas Pharma US INC | $63.00 | 2025 | Izervay |
| Optos Plc | $48.42 | 2020 | |
| Apellis Pharmaceuticals, INC. | $41.05 | 2022-2023 | Syfovre |
| Novartis Pharmaceuticals Corporation | $39.56 | 2019 | |
| Eyepoint US, INC. | $38.50 | 2022-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $22.86 | 2019 | |
| Bausch & Lomb Americas INC. | $20.07 | 2022 | |
| Boston Scientific Corporation | $20.07 | 2020 | |
| Sun Pharmaceutical Industries INC. | $15.78 | 2020 | |
| Merz North America, INC. | $14.00 | 2022 | |
| Allergan, INC. | $12.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandi Conway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.